BioLife Solutions, Inc. (NASDAQ:BLFS) Shares Bought by Curi RMB Capital LLC

Curi RMB Capital LLC increased its stake in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 2.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 433,815 shares of the medical equipment provider's stock after acquiring an additional 11,882 shares during the period. Curi RMB Capital LLC owned approximately 0.94% of BioLife Solutions worth $11,262,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. FMR LLC lifted its holdings in BioLife Solutions by 470.6% during the 3rd quarter. FMR LLC now owns 13,317 shares of the medical equipment provider's stock worth $333,000 after buying an additional 10,983 shares during the last quarter. Stifel Financial Corp lifted its stake in BioLife Solutions by 5.4% during the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider's stock worth $325,000 after purchasing an additional 670 shares during the last quarter. State Street Corp lifted its stake in BioLife Solutions by 7.3% during the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider's stock worth $35,364,000 after purchasing an additional 95,788 shares during the last quarter. Barclays PLC boosted its holdings in BioLife Solutions by 20.1% in the third quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider's stock valued at $1,613,000 after purchasing an additional 10,803 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in BioLife Solutions by 2.2% in the third quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider's stock valued at $21,107,000 after purchasing an additional 18,473 shares during the last quarter. Hedge funds and other institutional investors own 93.24% of the company's stock.

BioLife Solutions Stock Performance

Shares of NASDAQ:BLFS traded down $0.32 on Friday, reaching $24.48. The company's stock had a trading volume of 91,228 shares, compared to its average volume of 376,433. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. BioLife Solutions, Inc. has a 52-week low of $16.10 and a 52-week high of $29.55. The stock's 50-day moving average is $24.28 and its two-hundred day moving average is $25.22. The stock has a market capitalization of $1.16 billion, a P/E ratio of -23.08 and a beta of 1.93.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.32. The company had revenue of $22.71 million during the quarter, compared to analysts' expectations of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same period last year, the firm earned ($0.21) EPS. As a group, sell-side analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. HC Wainwright upped their target price on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a "buy" rating in a report on Thursday, March 6th. StockNews.com lowered BioLife Solutions from a "hold" rating to a "sell" rating in a report on Thursday. Finally, Northland Securities boosted their target price on BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $31.17.

Insider Buying and Selling at BioLife Solutions

In related news, CFO Troy Wichterman sold 4,151 shares of the firm's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total value of $103,775.00. Following the completion of the sale, the chief financial officer now owns 116,809 shares in the company, valued at $2,920,225. This trade represents a 3.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Sarah Aebersold sold 1,091 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total value of $27,275.00. Following the transaction, the insider now owns 58,816 shares in the company, valued at $1,470,400. The trade was a 1.82 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 72,127 shares of company stock valued at $1,676,533. 2.20% of the stock is owned by company insiders.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.